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Myelodysplastic syndromes (MDSs) represent a group of incurable stem-cell malignancies which are predominantly treated by
supportive care. Epigenetic silencing through promoter methylation of a number of genes is present in poor-risk subtypes of
MDS and often predicts transformation to acute myelogenous leukemia (AML). Azacitidine and decitabine, two FDA-approved
DNA methyltransferase (DNMT) inhibitors, are able to improve overall response although their oral bioavailability complicates
their clinical use. This study evaluated 2′, 3′, 5′-triacetyl-5-azacitidine (TAC) as a potential prodrug for azacitidine. The prodrug
demonstrated significant pharmacokinetic improvements in bioavailability, solubility, and stability over the parent compound.
In vivo analyses indicated a lack of general toxicity coupled with significantly improved survival. Pharmacodynamic analyses
confirmed its ability to suppress global methylation in vivo. These data indicate that esterified nucleoside derivatives may be
eﬀective prodrugs for azacitidine and encourages further investigation of TAC into its metabolism, activity, and possible clinical
evaluation.
1. Introduction
Currently, it is estimated that between 12,000 and 20,000 new
cases of MDS are diagnosed each year in the United States.
Although MDS can aﬀect all ages, the highest prevalence
occurs in those over 60 years of age [1, 2]. Much of the pop-
ulation has indolent forms of MDS, making it one of the
most prevalent hematologic malignancies of older adults.
MDS represents a heterogeneous group of hematopoietic
disorders which are derived from an abnormal multipotent
progenitor cell and are characterized by hyperprolifera-
tive bone marrow, cellular dysplasia, and ineﬀective hem-
atopoiesis [3]. Morbidity and mortality result from anemia,
bleeding, and infection, along with transformation to acute
myelogenous leukemia (AML) in approximately one-third
of patients [4, 5]. The basis of therapy is supportive
care, including red blood cell or platelet transfusions and
treatment of infections. Stem-cell transplantation remains
the only chance for cure, but it is associated with significant
treatment-related morbidity and mortality and is generally
restricted to patients <60 years of age [6]. Similar limitations
exist for the use of high dose chemotherapy. Given the
limitations of existing therapies, there is a clear need for
additional therapeutic options for patients with MDS.
Cancer cells are characterized by abnormal DNA methy-
lation patterns, and DNA hypermethylation is suspected
of being involved in MDS progression and leukemoge-
nesis. Therefore, inhibitors of DNA methylation repre-
sent a useful approach to revert these epigenetic chan-
ges. 5-azacitidine (Vidaza) and its derivative 5-aza-2′-
deoxycytidine/decitabine (Dacogen) are nucleoside analogs
with DNA hypomethylating activity that have been FDA-
approved during the past 5-6 years for MDS treatment
[7, 8]. They appear to induce re-expression of key tumor
suppressor genes in MDS [9]. Compared to supportive care,
both agents show an improved overall response (60% versus
5%), a longer time to progression to AML or death, but still
with limited overall survival advantage [10]. Azacitidine has
been developed for the treatment of acute leukemia and is
currently being evaluated in a variety of other disorders [11].
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DNA methylation results in the addition of a methyl
group at the carbon 5 position of the cytosine ring in CpG
dinucleotides, which is critical to chromatin structure and
genomic stability [12]. Since 5-methyl cytosine can be deam-
inated to thymidine, DNA hypermethylation also facilitates
gene mutations in human cancers [13]. The transferring
of methyl groups from S-adenosylmethionine to cytosine
is catalyzed by DNA methyltransferases, the best known of
which is DNMT1. The inactivation of DNMTs has been
shown to be the most eﬀective method of inhibiting DNA
methylation although it is recognized that this approach
lacks specificity. However, inhibiting the activity of DNMTs
has resulted in the abrogation of tumorigenicity in murine
cancer models [14].
DNMT-inhibiting nucleoside analogs require metabo-
lism by kinases into nucleotides before their incorporation
into DNA and/or RNA in order to inhibit DNA methylation.
The modification at C5 prevents the release of DNMTs by
forming a covalent complex, preventing further DNA meth-
ylation and consequently the DNA of the progeny cells is not
methylated [15]. Azacitidine and Decitabine are extremely
potent in inhibiting DNA methylation, but their short half-
lives in aqueous solutions [16, 17] and low oral bioavail-
ability complicate their delivery. For years, these drugs
used as antineoplastic agents in leukemias were escalated to
maximum tolerated doses (MTD) [18]; however, recent
clinical trials have confirmed that low-dose exposures lead
to greater responses and are associated with less toxicity
[19, 20].
In an eﬀort to overcome the stability and pharmacoki-
netic limitations, a number of groups are working to develop
oral DNMT inhibitors, including oral forms of decitabine
and azacitidine. As a proof of principle we have synthesized
an acetylated derivative of azacitidine, 2′,3′,5′-triacetyl-5-
azacitidine (TAC) to evaluate as an oral prodrug. While
this is not a totally new approach, it was never utilized
for this derivative and in this set of diseases. Our cur-
rent study demonstrates that 2′,3′,5′-triacetyl-5-azacitidine
(TAC) eﬀectively inhibits methylation and improves life
expectancies in murine models while demonstrating lower
toxicity when compared to its parent compound, azacitidine.
2. Materials and Methods
2.1. Preparation of 2′,3′,5′-Triacetyl-5-Azacitidine (TAC)
[21]. TAC was prepared through condensation of trimeth-
ylsilylated-5-azacytosine and 1,2,3,5-tetra-O-acetyl-β-D-
ribofuranose. In a 150mL, 3-necked flask, a mixture of 5-
azacytosine, hexamethyldisilazane, and ammonium sulfate
was heated at reflux for 2 hours. A fresh amount of
ammonium sulfate was added, and the reflux was continued
for 6 hours. The excess hexamethyldisilazane was removed
under reduced vacuum to aﬀord trimethylsilylated 5-
azacytosine as an oﬀ-white residue.
Tetra-O-acetyl-D-ribofuranose was prepared by adding
acetic anhydride dropwise to D-ribose dissolved in dry
pyridine. The solvent was removed by heating the solution
at 50◦C for 15 minutes, and tetra-O-acetyl-D-ribofuranose
was crystallized from isopropanol [22].
Trimethylsilylated 5-azacytosine and 1,2,3,5-Tetra-O-
acetyl-β-D-ribofuranose were dissolved in acetonitrile, and
the mixture was cooled at 0◦C in an ice-water bath. Tri-
methylsilyl trifluoromethanesulfonate (TMSOTf) was added
slowly at 0◦C then stirred at room temperature for 3
hours. The reaction mixture was poured into a solution
of Na2CO3 and NaHCO3 in ice water and then extracted
with dichloromethane. The combined organic layer was
washed with cold H2O, cold brine, and dried over anhydrous
Na2SO4. The residue, after removal of the solvent, was re-
crystallized from a mixture of dichloromethane and hexane
to provide the desired compound with an 85% yield.
2.2. LC/MS/MS Analysis of TAC and Its Metabolites Mono-
and Di-Acetyl-5-Azacitidine and ACT. To monitor the in
vivo absorption, distribution, and metabolism of TAC, a
highly sensitive LC/MS/MS analytical method was developed
that allows the quantitation of concentrations as low as
10 ng/mL of TAC and its metabolites. The samples were pre-
pared by adding 200 μL of plasma to 400 μL of cold
acetonitrile, vortexed, and centrifuged at 14,000 rpm for 10
minutes. The supernatant was placed into a 10×75mm glass
test tube and evaporated to 50 μL under nitrogen at 37◦C.
The residue was then diluted with 1mL of 2% phosphoric
acid and vortexed for 10 seconds at 3,000 rpm.
Solid phase extraction was conducted using a Varian
Bond Elute PLEXA PCX 1mL columns placed on a vacuum
manifold. Columns were activated by adding 1mL of MeOH
followed by 1mL H2O and 1mL of 2% phosphoric acid.
All samples were allowed to drip by gravity flow. The
extraction columns were then washed sequentially with 1mL
2% phosphoric acid, 1mL H2O, and 1mL MeOH/AcCN
(1/1) and eluted into a 10× 75mm glass test tube containing
50 μL of 25% formic acid in MeOH with 2 × 600 μL of
2% NH4OH in MeOH/AcCN (1/1). The liquid was then
evaporated to dryness with nitrogen at 37◦C, and 100 μL of
mobile phase A was added and vortexed for 10 seconds at
3,000 rpm and transferred to LC autosampler vials at 4◦C.
HPLC separation was conducted on a reverse phase
C18 column (Varian Pursuit C18, 3 micron particle size;
100mm × 2.0mm) using a Shimadzu SIL-HTc controller
with dual LC-20AD pumps and DGU-20A3 degasser. The
separation was achieved using a gradient of Mobile Phase A:
0.1% Formic Acid and Mobile Phase B: 0.1% Formic Acid,
90% MeOH with a flow rate of 400 μL/min at 40◦C over
10 minutes. MS/MS fragmentation was performed on an
Applied Biosystems API 3200 instrument with a Turbo V Ion
Spray ion source and Positive ion polarity.
2.3. Drug Stability. ACT and TAC stabilities were determined
after incubation at pH1 (2% Phosphoric acid), pH3 (0.1%
Formic Acid), pH5 (K3PO4), and pH7.4 (Dulbecco’s PBS).
100 ng of each compound was resuspended in 1.2mL total
volume, and 200 μL samples taken at 1, 3, 6, 29, and 48 hr.
Each pH point was repeated 6 times in 2 dram vials with
Teflon-lined screw caps at room temperature. Samples were
extracted by solid-phase extraction using 100 ng decitabine
as an internal standard and analyzed by tandem mass spec-
troscopy as described above.
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2.4. Log P Determination. The OSIRIS Property Explorer
software was used to generate initial cLogP values. The par-
tition coeﬃcient was determined by using an analyte concen-
tration near the solubility limit for the compound in water
and incubating in a water : octanol mix ranging from 0.5 : 1,
1 : 1, to 2 : 1. The pH of the water was 2 units above the pKa
of the compound, preventing ionization. The experiment
was conducted using the shake-flask method, after allowing
octanol and water to equilibrate for 24 hours at 25◦C.
The initial drug concentration in water was 0.2mM. Tubes
were rotated at a 45 degree angle for 10 minutes with a
3 second rotation. The test was performed in a constant
environment of 20◦C–25◦C. Tubes were centrifuged at 1000 g
for 10 minutes, and the octanol phase was extracted. The
UV/Visible absorption spectrum was evaluated from 550 nm
to 210 nm to determine the absorption maximum. The ana-
lyte concentration was determined and the LogP calculated:
Log = log(concentration in octanol/concentration in water).
2.5. Permeability across Caco-2 Monolayers. Caco-2 cells
(ATCC) were maintained under standard conditions in Dul-
becco’s modified Eagle’s medium (DMEM). Approximately 1
× 105 cells (passage number 25–35) were seeded onto poly-
carbonate cell culture inserts (Transwell, 0.45 μm, 12mm
diameter). The cells were allowed to grow and diﬀerentiate
for three weeks changing the medium every 2-3 days.
Lucifer yellow was used to ensure appropriate paracellular
permeability levels [23].
The transport experiments were performed in Hanks’
balanced salt solution (HBSS) containing 25mM Hepes (pH
7.4) as thoroughly described [24]. The drugs were dissolved
in transport buﬀer to a final concentration of 0.2mM. The
monolayers were washed in prewarmed transport buﬀer for
30min. The drug solutions were added to the donor side of
the monolayers, and fresh transport buﬀer was added to the
receiver side. The plates were gently shaken (50–100 rpm)
at 37◦C. At time intervals ranging from 5 minutes up to
2 h, 0.2mL samples were collected from the receiver cham-
bers and replenished with fresh transport buﬀer. Samples
containing the transported drug was collected for LC/MS
analysis by immediately freezing at −80◦C and subsequently
extracted 2 : 1 with acetonitrile and analyzed as indicated in
the LC/MS/MS methodology section.
2.6. Pharmacokinetics and Metabolism of TAC in Mice. To
evaluate the in vivo pharmacokinetic properties of TAC,
C57/BL6 female mice of 20 g body weight were dosed with
38mg/kg TAC p.o. (equimolar dose to 25mg/kg of ACT) or
25mg/kg ACT i.v. via tail vein injection. TAC and ACT were
solubilized in 1X PBS immediately before administration and
dosed at 0.01mL/g fasted body weight. Blood samples (two
time points per animal, three animals per time point) were
obtained via retro-orbital bleeding with Natelson pipettes
at 0.5, 1, 2, 4, 8, and 24 hours after drug administration.
The collected blood was then centrifuged for 4 minutes
at 13,000 g. Plasma was immediately extracted with cold
acetonitrile and stored at −80◦C until LC/MS/MS analysis.
Noncompartmental plasma pharmacokinetic parameters
for TAC prodrug and ACT after oral TAC or i.v ACT
administrations were estimated using the sparse sampling
option in WinNonlin Software version 4.1 (Pharsight Corp.,
Mountain View, Calif, USA). Briefly, the WinNonlin sparse
sampling option applies the linear trapezoidal rule for area
under the concentration-time curve (AUC) calculations and
generates a standard error for the mean AUC estimate
that accounts for correlations in the data resulting from
repeated sampling of individual mice. Parameters of interest
included the AUC from time 0 to the last measurable
concentration (AUClast), observed peak concentration after
oral administration (Cmax), estimated peak concentration
after i.v. administration (C0), mean residence time to the
last measurable concentration (MRTlast), and the half-life of
the terminal phase (T1/2). To assess the multiphasic decline
in plasma concentrations, an alpha (T1/2α) half-life was also
estimated using a log-linear regression of the mean ACT
concentrations through 2 hours after dosing.
2.7. Global Methylation Detection Assay. 24 hours follow-
ing drug administration, snap-frozen mouse tissues were
homogenized and genomic DNA isolated using Promega’s
Wizard Genomic DNA Purification Kit. 100 ng of EcoRI
linearized genomic DNAwas spotted onto PVDFmembrane.
The membrane was air-dried and repermeabilized according
to manufacturer’s instructions. Nonspecific binding was
blocked using 5% milk in PBS-T and washed twice in
PBS-T for 5 minutes. The membrane was incubated with
primary antibody (1 : 1000 anti-5-methylcytosine in PBS-T,
Calbiochem) for 1 hour then washed four times for five min-
utes each with PBS-T. Themembrane was incubated with the
HRP-conjugated secondary antibody for 1 hour and washed
four times for five minutes each with PBS-T. Signal intensity
following ECL detection was quantitated using KODAK
Image Station software. Assay results were confirmed using
EpiGentek’s Methylamp Global DNA Methylation Quantifi-
cation Kit per manufacturer’s instructions.
2.8. p15INK4B Methylation Status. Mouse leukemia cells
(L1210) were purchased from ATCC. The published IC50
value for ACT (0.2 uM) was first confirmed using the
Promega CellTiter MTS assay. Cells were treated with ACT
(0.1 or 1 uM) or TAC (1 or 100 uM) for 48 hours, with fresh
drug added daily. Genomic DNA was isolated after 48 hours
using the Sigma GenElute Genomic DNA Kit, including
the RNase treatment step to ensure no RNA carryover. The
methylation status of p15INK4B was determined using a
predesigned primer set and the EpiTect Methyl qPCR Assays
MethylScreen technology (Qiagen, Frederick, Md, USA).
2.9. Antileukemic Activity of Triacetyl-5-Azacitidine. The in
vivo L1210 lymphocytic leukemia model in C57BL/6 ×
DBA/2 F1(BDF1) female mice was used to evaluate the
in vivo antiproliferative eﬀect of TAC. L1210 cells were
carried in BDF1 mice by weekly i.p. (intraperitoneal) pas-
sages. Leukemia cells from ascites fluid were diluted ap-
propriately in RPMI 1610 medium and injected i.p.
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Figure 1: Chemical synthesis of 2′,3′,5′-triacetyl-5-Azacytidine.
Results of analytical 1H NMR (CDCl3, 500MHz): d 8.18(s, 1H),
7.69(s, 1H), 6.33(s, 1H), 5.82(d, 1H, J = 3.0Hz), 5.54(t, 1H, J =
4.0Hz), 5.41(t, 1H, J = 6.0Hz), 4.30–4.41(m, 3H), 2.11(s, 3H),
2.10(s, 3H), and 2.08(s, 3H) ppm. 13C NMR (CDCl3, 125MHz):
d 170.3, 169.6, 169.5, 166.0, 156.0, 153.1, 89.7, 79.9, 73.7, 69.9, 62.8,
20.7, 20.4, and 20.3 ppm.
(1×105 cells/0.1mL/mouse) into recipient mice. A daily oral
administration of TAC (38mg/kg via oral gavage) or ACT
(25mg/kg administered i.p.) diluted in PBS was given to
leukemic BDF1 mice starting 24 hours from the inoculation
of L1210 cells for a total of 5 days. Compounds were prepared
fresh daily. A group of untreated leukemic mice received
sterile water for injections and served as controls.
2.10. TAC Toxicology. The in vivo toxicity of TAC was eval-
uated in CD-1 mice using 3 groups of 3 male and 3 female
CD-1 mice per group. CD-1 is the classical mouse strain
chosen for toxicology studies including safety and eﬃcacy.
On Days 1–5 and Days 8–12, animals were administered
vehicle (sterile water for injection, Group 1), 38mg/kg/day
TAC (Group 2), or 76mg/kg/day TAC (Group 3) via oral
gavage. Animals were not dosed on Days 6 and 7 and were
euthanized on Day 13 for necropsy. Doses were prepared
fresh daily from the drug stock. Criteria for evaluation
included clinical observations, body weights, limited serum
chemistry and hematology parameters, and histopathology
evaluation.
3. Results
3.1. Synthesis and In Vitro Characterization of Triacetyl-5-
Azacitidine. 2′,3′,5′-triacetyl-5-azacitidine has been success-
fully synthesized through condensation of trimethylsilylated-
5-azacytosine and 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose
(Figure 1). An HPLC detection assay was optimized for TAC
and ACT as well as some potential analytes.
The solubility of TAC in comparison to ACT was
evaluated at various pH. TAC and ACT were equally soluble
at pH1 (40mg/mL) and pH3 (25mg/mL), while TAC was
more soluble than ACT at pH5 (30mg/mL versus 15mg/mL)
and pH7 (30mg/mL versus 10mg/mL). The stability of the
prodrug across a range of pHs is indicated in Table 1. TAC
shows remarkable stability at pH 3, 5, and 7.4 with no
degradation to the parent compound and 30% hydrolysis to
themono- and diesters only at pH 7.4 after a 29 hr incubation
at 25◦C. At pH 1, we observed a moderate hydrolysis of
Table 1: Stability of TAC and its metabolites at various pH.
Sample TAC (%) DAC (%) MAC (%) ACT (%)
Control 100
pH 1—1hr 99 1 0 0
pH 1—3hr 74 22 4 0
pH 1—6hr 38 41 21 0
pH 1—29 hr 1 22 31 46
pH 3—1hr 97 3 0 0
pH 3—3hr 96 4 0 0
pH 3—6hr 92 6 2 0
pH 3—29 hr 93 4 2 1
pH 5—1hr 98 2 0 0
pH 5—3hr 94 6 0 0
pH 5—6hr 98 2 0 0
pH 5—29 hr 94 4 1 1
pH 7.4—1hr 96 4 0 0
pH 7.4—3hr 91 7 2 0
pH 7.4—6hr 85 12 3 0
pH 7.4—29 hr 69 17 13 1
TAC: tri-acetyl-azacitidine; DAC: di-acetyl-azacitidine; MAC: mono-acetyl-
azacitidine; ACT: azacitidine.
TAC (26%) to the mono- and diesters in the first 3 hours
of incubation increasing to 60% after 6 hrs. However, after
24, 99% of TAC was hydrolyzed, including 46% to the parent
compound, ACT.
A similar experiment to establish the stability of azaci-
tidine in solution resulted in significant degradation of the
nucleoside analog throughout the pH range with maximum
stability at pH 1. As previously determined, [25] the
initial degradation to N-formylguanylribosylurea followed
by the irreversible formation of guanylribosylurea resulted in
two derivatives with no pharmacological activity (data not
shown).
3.2. LogP Determination. The logP value of a compound is
a well established measure of a compound’s hydrophilicity.
The theoretical physical-chemical properties of TAC were
evaluated by measuring the partition coeﬃcient of the un-
ionized molecules in two immiscible phases of water and
octanol. Azacitidine resulted in an experimental LogP value
of −2.32 compared to the calculated cLogP values of −2.17
while the changes to the molecule by acetylation resulted in
an improved LogP value for TAC of −0.61 versus a cLogP of
−0.85.
3.3. Permeability across Caco-2 Monolayers. The human
colon carcinoma Caco-2 cell model was used to evaluate the
oral absorption of the prodrug across membranes and deter-
mine the permeability coeﬃcient (absorption rate constant).
A sigmoidal relationship exists between drug absorption
rates as measured with the in vitro Caco-2 model and human
absorption [26]. Permeability coeﬃcients typically range
from 5× 10−8 to 5× 10−5 cm/s. Drugs that are well absorbed
in humans have permeability coeﬃcients greater than
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1 × 10−6 cm/s, while drugs and peptides that are absorbed
to less than 1% have permeability coeﬃcients less than
1 × 10−7 cm/s [27, 28]. Between these ranges, compounds
are considered to have intermediate absorption rates. In
these studies, ACT was determined to have a permeability
coeﬃcient between 1–3 × 10−6, compared to 5–7 × 10−6
for TAC. This indicates a potential 2-3 fold improvement
in intestinal absorption. The eﬄux ratio is defined as the
quotient of the secretory permeability and the absorptive
permeability. The eﬄux ratio was near 1.0, indicating these
compounds are not being actively eﬄuxed. No hydrolysis of
the prodrug to azacitidine was observed during the course of
this experiment.
3.4. Pharmacokinetics and Metabolism of TAC in Mice. TAC
was administered at 38mg/kg to C57/BL6 mice via oral gav-
age, an equimolar dose equivalent to 25mg/kg of azacitidine.
TAC and its active metabolite ACT were detectable in plasma
at 30 minutes after the oral administration (Figure 2(a)).
TAC appeared to be rapidly deacetylated leading to aminimal
accumulation of the prodrug resulting in plasma concen-
trations below the limit of quantitation (10 ng/mL) at time
points beyond 1 hour after administration. TAC-derived
azacitidine reached a peak concentration of approximately
5,000 ng/mL (∼20 μM) at 30 minutes with a pharmacologi-
cally relevant concentration of at least 0.5 μMbeing sustained
for 24 hours after oral TAC dosing. The mean TAC and
TAC-derived ACT plasma concentrations versus time plots
after oral administration of TAC prodrug are depicted in
Figure 2(a) with the pharmacokinetic parameters reported in
Figure 2(b). ACT was also administered i.v. as a control to
emulate the standard means of administration in the clinical
setting. The T1/2 and MRTlast values for TAC-derived azaciti-
dine were 9.2 hours and 7.7 hours, respectively, whereas i.v.
administration of ACT resulted in T1/2 and MRTlast values
of 6.8 hours and 1.1 hours, respectively. The AUClast values
for plasma azacitidine were 73.5 hr-μM and 126 hr-μM after
oral administration of TAC prodrug or i.v. administration
of ACT, respectively. While the absolute bioavailability of
derived azacitidine after oral TAC administration is 58%, the
prolonged T1/2 and MRTlast values for azacitidine observed
in plasma after oral TAC administration suggest a protracted
absorption and conversion of the TAC prodrug at the
gastrointestinal or presystemic level (Figure 2(b)). The log-
linear regression analysis of ACT concentration data through
2 hours revealed an increased T1/2α value for ACT after p.o.
TAC administration compared with i.v. ACT administration
(0.73 hr versus 0.32 hr, resp.), also suggesting protracted
absorption and both presystemic and systemic conversion of
TAC.
3.5. Pharmacodynamic Eﬀect of Triacetyl-5-Azacitidine. MTS
assays (Promega, Madison, Wis, USA) were performed to
determine the in vitro eﬀects of ACT and TAC on L1210
cell proliferation. TAC had no eﬀect on L1210 cell viability
even at doses 100-fold higher than the known IC50 of ACT
(0.2 uM) [29], and this is an indication that this compound
does not get activated in vitro. This result was predicted, since
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Figure 2: Pharmacokinetics of oral TAC versus i.v. 5-azacitidine in
C57BL/6 mice. (a) Mean plasma concentration versus time for tri-
acetyl azacytidine (TAC) () and resultant ACT (•) in nontumor
bearing mice after a 38mg/kg dose of oral TAC. Mean plasma
concentration versus time for ACT in nontumor bearing mice after
25mg/kg ACT i.v. (◦). Error bars indicate standard deviation. (b)
Noncompartmental plasma pharmacokinetic parameters for azac-
itidine (ACT) and tri-acetyl azacitidine (TAC). AUClast values are
mean (standard error). NE—not estimated. NC—not calculated.
cells in culture lack the necessary esterase activity to convert
the prodrug to ACT that remains below the limit of detection
using our LC-MS method.
Gene-specific methylation PCR was performed in order
to confirm whether TAC could aﬀect the methylation level of
a specific target even in the absence of cellular toxicity. ACT,
which is the active derivative of TAC, has been extensively
studied by numerous research groups to determine specific
cellular methylation targets and mechanism of action [30,
31]. P15INK4B is a classic target known to be hyper-
methylated in AML and MDS and attributes to a poor
prognosis in those patients [32, 33]. 0.1 uM and 10 uM ACT
decreased P15 promoter methylation by 39% (±3) and 49%
(±17), respectively. In comparison, 1 uM and 100 uM TAC
decreased P15 promoter methylation by only 19% (±8) and
23% (±16), respectively.
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Figure 3: Eﬀect of DNMT inhibitors on global DNA methylation
in tissues of mice exposed for 5 days to ACT or TAC. (a) Dot blot
of mouse tissues isolated 24 hours after treatment with 25mg/kg
i.v. ACT or 38mg/kg p.o. TAC. Groups were compared to untreated
animals (unt). (b) Densitometry of methylation levels represented
in (a).
In an in vivo experiment designed to evaluate the eﬀect
of a prolonged administration of TAC on global methylation,
TAC (38mg/kg p.o.) or ACT (25mg/kg i.p.) diluted in
PBS was administered to C57BL6 mice every 24 hours for
5 consecutive days (four animals per group). Tissue methyla-
tion levels are reported in Figure 3. A significant reduction
in global DNA methylation was detected in the gut and
spleen after the administration of TAC, comparable to the
methylation decrease detected after the administration of
ACT. We did not observe a significant change in global
methylation status in kidney or liver tissue (data not shown).
The positive results in gut and spleen were confirmed
using the EpiGentek’s Methylamp Global DNA Methylation
Quantification Kit. This quantitative analysis confirmed a
comparable 50%–60% decrease in global methylation by
both TAC and ACT (data not shown).
3.6. Antileukemic Activity of Triacetyl-5-Azacitidine. The
L1210 lymphocytic leukemia model was used to determine
the eﬃcacy of TAC in an animal model. The L1210 model
is a classical model used to predict for compounds that
are eﬀective against leukemias and lymphomas. A daily oral
administration of TAC (38mg/kg equimolar to 25mg/kg
of ACT and a higher dose of 50mg/kg) or azacitidine i.p.
(25mg/kg) was given to leukemic mice for a total of 5 days.
The median survival time for the untreated control group
was 8 days, while the median survival time for the TAC
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Figure 4: (a) Antileukemic activity of TAC and ACT in BDF1 mice
bearing L1210 lymphocytic leukemia cells after 5 days of treatment
with indicated concentrations of oral TAC or i.p. ACT. (b) Toxic
eﬀect as indicated by average weight loss of the same tumor bearing
mice.
treated groups was 12 days resulting in a 50% increased
lifespan, demonstrating not only an epigenetic modulating
eﬀect, but also antileukemic activity. Azacitidine at the
maximum tolerated dose of 25mg/kg administered i.p.
resulted in a 17-day survival with a 112% increased lifespan
(Figure 4(a)). The toxicity curve (Figure 4(b)) indicates a
nonsignificant weight loss for the TAC-treated groups at day
3 followed by a rapid recovery indicating the lack of toxicity
of this prodrug coupled with a significant antileukemic eﬀect,
while the azacitidine-treated animal showed a 16% weight
reduction with a significant recovery once the treatment was
completed.
3.7. TAC Toxicology. The in vivo toxicity of TAC was eval-
uated by orally administering repeated doses to CD-1 mice
for two weeks. On Days 1–5 and Days 8–12, animals
were administered vehicle, 38mg/kg/day TAC (Group 2,
equivalent to 25mg/kg of ACT), or 76mg/kg/day TAC
(Group 3) via oral gavage. Criteria for evaluation included
clinical observations, body weights, limited serum chemistry
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Figure 5: TAC-associated eﬀect on hematological parameters
following TAC administration to CD-1 mice. RTC: reticulocyte
count, WBC: white blood cell count, NEU: neutrophil count, LYM:
lymphocyte count, MNO: monocyte count, EOS: eosinophil count,
LUC: large unstained cell count.
and hematology parameters, and histopathology evaluation
of a limited number of tissues from vehicle-treated and
76mg/kg/day TAC-treated animals.
There were no deaths and no notable TAC-associated
body weight changes during the study. Additionally, there
were no TAC-associated changes in liver or renal function
markers, including alanine and aspartate aminotransferases,
alkaline phosphatase, bilirubin, blood urea nitrogen, and
creatinine.
TAC-associated changes in various hematological param-
eters were observed (Figure 5). This included a reduction in
white blood cell counts, absolute lymphocytes, and absolute
leukocytes by 41%, 31%, and 24%, respectively, for the
38mg/kg/day dosage group. The reduction values for the
76mg/kg/day group only slightly increased by 44%, 31%,
and 34%, respectively. There were TAC-related findings
in the bone marrow (hypocellularity) and in the lymph
nodes (inactive germinal centers) which reflect the decreased
overall white blood cell count reductions. An additional
microscopic TAC-related finding was duodenum apoptosis
of the crypt epithelium in the 76mg/kg/day-treated animals.
Other observations included a decrease in myeloid and ery-
throid compartment cellularity correlating with microscopic
findings in various tissues.
4. Discussion
Epigenetic modulators are appealing cancer therapeutics due
to their potential reversibility and preference for highly
proliferating cancer cells. Azacitidine and decitabine have
demonstrated improved clinical success in hematologic ma-
lignancies with longer or continuous infusion [34]. However,
the aza-pyrimidine ring is unstable in aqueous solutions and
has poor bioavailability, limiting the use of oral formulations
that would be more convenient for the patients, help in long-
term dosing, and reduce local side eﬀects when administered
as subcutaneous depot.
We have successfully synthesized an azacitidine pro-
drug, 2′,3′,5′-triacetyl-5-azacitidine and shown its favorable
physical-chemical characteristics. TAC has demonstrated
higher solubility and stability in vitro across a wide pH
range compared to its parent compound azacitidine, which
is of great benefit for avoiding rapid degradation in the
acidic environment of the stomach and the more neutral
environment of the periphery. TAC has also shown a more
favorable logP. While LogP values may not always be a
completely accurate determination of the lipophilicity of
ionizable compounds, the data confirm the eﬃcient drug
absorption at the gastrointestinal level and bioavailability
observed.
In vivo analyses were performed comparing the desired
oral version of the prodrug with the classical administration
route of ACT (i.v. or subcutaneous). The stability and
bioavailability of the prodrug was confirmed in vivo, where
oral TAC-derived azacitidine had a terminal half-life of 9.2
hours versus 6.8 hours for i.v. administered azacitidine.
Additionally, the alpha phase half-life (T1/2α) value after
oral TAC administration was longer compared with i.v.
ACT—0.73 hr versus 0.32 hr, respectively. The half-life values
indicate a protracted absorption of the nucleoside prodrug
at the gastrointestinal level and an eﬀective conversion
by serum esterases. This may allow maintenance of ACT
concentrations over a 24-hour period as opposed to roughly
6 hours for i.v. ACT. The half-life of azacitidine in this
murine model is longer in our study compared to some
of the previous literature [35, 36]. This is likely due to
an improved sensitivity of our analytical methodology that
allows monitoring the concentration of azacitidine below
100 ng/mL.
TAC also demonstrated a pharmacodynamic eﬀect in
vivo. Oral TAC appears comparable to i.v. AC in its ability
to suppress global methylation in normal tissues. Further
analysis will be necessary to determine if this is a tissue-
specific eﬀect or eﬀective in altering the methylation status
of cancer cells and to identify specific gene targets. TAC
was less eﬀective than ACT at improving life span in the
leukemic L1210 animal model, possibly due to a higher Cmax
achieved by i.p. administration compared to oral, confirming
the dichotomy between epigenetic therapy that is eﬀective at
low extended doses versus the cytotoxic eﬀect achieved with
higher doses and linked to a higher Cmax [37].
Animals administered TAC for 2 weeks resulted in no
deaths and no weight loss, indicating minimal general tox-
icity. However, TAC did induce the expected changes in
hematological parameters, bone marrow, and lymph nodes.
Gastrointestinal toxicity was observed at the higher TAC
dose with duodenum apoptosis of the crypt epithelium.
This eﬀect is possibly due to the localized hydrolysis of
the prodrug with formation of azacitidine known to cause
gastrointestinal toxicities in patients. Several have attempted
to overcome the lack of stability and poor bioavailability
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of the current DNMT inhibitors. Oral formulations of
azacitidine and decitabine have not been successful due
to their hydrolysis in the aqueous environment of the
intestinal tract and rapid deamination. An oral film-coated
formulation of azacitidine has been recently evaluated in
four human subjects resulting in 17.4% bioavailability for
an 80mg dose with a mean plasma half-life of 0.39 hr versus
0.68 hr for a subcutaneous formulation [38]. A very recent
Phase I study of oral azacitidine showed a high interpatient
variability in the bioavailability of azacitidine ranging from
6.3% to 20% (33) indicating the need for a more controlled
delivery [39].
Other groups have proposed modification of the struc-
ture at the N4 position such as the addition of a 2-
(p-nitrophenyl)ethoxycarbonyl group (NPEOC) to protect
the azacytosine ring [40]. This derivative is similar to
the 5-FU prodrug capecitabine. The N4-NPEOC-5-aza-2′-
deoxycytidine has been shown to be activated to decitabine
resulting in global and gene-specific DNA demethylation
in cells expressing carboxylesterase 1 [41]. The NPEOC
derivatives are characterized by very low solubility in water
and their elevated hydrophobicity could lead to an improved
oral bioavailability; however, in vivo data in animal models
or humans are not available [40]. Protection of the N4 has
also been achieved in sapacitabine by incorporating a N4-
palmitoyl group of (1-(2-C-cyano-2-deoxy-β-D-arabino-
pentafuranosyl) cytosine (CNDAC). This modification has
resulted in better diﬀusion into gastrointestinal cells allowing
the oral administration of the drug [42]. A Phase I study
of oral sapacitabine confirmed its metabolism to CNDAC;
however, it resulted in pharmacokinetic variability possibly
due to diﬀerences in absorption or metabolism [43].
To improve the stability characteristics of decitabine and
increase its intracellular delivery, the nucleoside analog has
been incorporated into a guanine dinucleotide to generate
S110 (5′-AzapG-3′). S110 has shown stability in aqueous
solutions and toxicity comparable to that of decitabine with
increased resistance to enzymatic degradation (deamination)
before incorporation into DNA following endonuclease
and/or phosphodiesterase cleavage [44].
We have synthesized and evaluated an acetylated deriva-
tive of azacitidine, 2′,3′,5′-triacetyl-5-azacitidine (TAC) as
an oral prodrug. While this is not a totally new approach,
it was never utilized for this derivative and in this set of
diseases. A few examples exist in the literature of this type
of derivatization for the oral delivery of pyrimidine analogs.
Triacetyl-6-azauridine was developed to overcome the poor
oral absorption of azauridine, an antipsoriasis drug [45].
2′,3′,5′-tri-O-acetyluridine (PN401) was synthesized as a
rescue agent for 5-fluorouracil-based therapies [46, 47].
Taken together, our data indicate the triacetylated deriva-
tive of azacitidine may be an eﬀective prodrug that could
allow continuous exposure to azacitidine at low doses result-
ing in a protracted DNA hypomethylation. The superior
stability and solubility of TAC, together with its minimal
toxicity, will encourage the further investigation of its
mechanism of action, its epigenetic modulatory eﬀect, and
its ability to slow down the progression of MDS into AML.
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